A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis
De novo purine nucleotide biosynthesis (DNPNB) consists of sequential reactions that are majorly conserved in living organisms. Several regulation events take place to maintain physiological concentrations of adenylate and guanylate nucleotides in cells and to fine-tune the production of purine nucl...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1329011/full |
| _version_ | 1797302427063418880 |
|---|---|
| author | Nour Ayoub Antoine Gedeon Hélène Munier-Lehmann |
| author_facet | Nour Ayoub Antoine Gedeon Hélène Munier-Lehmann |
| author_sort | Nour Ayoub |
| collection | DOAJ |
| description | De novo purine nucleotide biosynthesis (DNPNB) consists of sequential reactions that are majorly conserved in living organisms. Several regulation events take place to maintain physiological concentrations of adenylate and guanylate nucleotides in cells and to fine-tune the production of purine nucleotides in response to changing cellular demands. Recent years have seen a renewed interest in the DNPNB enzymes, with some being highlighted as promising targets for therapeutic molecules. Herein, a review of two newly revealed modes of regulation of the DNPNB pathway has been carried out: i) the unprecedent allosteric regulation of one of the limiting enzymes of the pathway named inosine 5′-monophosphate dehydrogenase (IMPDH), and ii) the supramolecular assembly of DNPNB enzymes. Moreover, recent advances that revealed the therapeutic potential of DNPNB enzymes in bacteria could open the road for the pharmacological development of novel antibiotics. |
| first_indexed | 2024-03-07T23:37:43Z |
| format | Article |
| id | doaj.art-a46d36049572414686c3f9c4b69993a4 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-07T23:37:43Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-a46d36049572414686c3f9c4b69993a42024-02-20T05:58:06ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-02-011510.3389/fphar.2024.13290111329011A journey into the regulatory secrets of the de novo purine nucleotide biosynthesisNour Ayoub0Antoine Gedeon1Hélène Munier-Lehmann2Institut Pasteur, Université Paris Cité, INSERM UMRS-1124, Paris, FranceSorbonne Université, École Normale Supérieure, Université PSL, CNRS UMR7203, Laboratoire des Biomolécules, LBM, Paris, FranceInstitut Pasteur, Université Paris Cité, INSERM UMRS-1124, Paris, FranceDe novo purine nucleotide biosynthesis (DNPNB) consists of sequential reactions that are majorly conserved in living organisms. Several regulation events take place to maintain physiological concentrations of adenylate and guanylate nucleotides in cells and to fine-tune the production of purine nucleotides in response to changing cellular demands. Recent years have seen a renewed interest in the DNPNB enzymes, with some being highlighted as promising targets for therapeutic molecules. Herein, a review of two newly revealed modes of regulation of the DNPNB pathway has been carried out: i) the unprecedent allosteric regulation of one of the limiting enzymes of the pathway named inosine 5′-monophosphate dehydrogenase (IMPDH), and ii) the supramolecular assembly of DNPNB enzymes. Moreover, recent advances that revealed the therapeutic potential of DNPNB enzymes in bacteria could open the road for the pharmacological development of novel antibiotics.https://www.frontiersin.org/articles/10.3389/fphar.2024.1329011/fullallosteryantibacterial agentschemical compoundsenzyme regulationIMP dehydrogenasenucleotide biosynthesis |
| spellingShingle | Nour Ayoub Antoine Gedeon Hélène Munier-Lehmann A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis Frontiers in Pharmacology allostery antibacterial agents chemical compounds enzyme regulation IMP dehydrogenase nucleotide biosynthesis |
| title | A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis |
| title_full | A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis |
| title_fullStr | A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis |
| title_full_unstemmed | A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis |
| title_short | A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis |
| title_sort | journey into the regulatory secrets of the de novo purine nucleotide biosynthesis |
| topic | allostery antibacterial agents chemical compounds enzyme regulation IMP dehydrogenase nucleotide biosynthesis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1329011/full |
| work_keys_str_mv | AT nourayoub ajourneyintotheregulatorysecretsofthedenovopurinenucleotidebiosynthesis AT antoinegedeon ajourneyintotheregulatorysecretsofthedenovopurinenucleotidebiosynthesis AT helenemunierlehmann ajourneyintotheregulatorysecretsofthedenovopurinenucleotidebiosynthesis AT nourayoub journeyintotheregulatorysecretsofthedenovopurinenucleotidebiosynthesis AT antoinegedeon journeyintotheregulatorysecretsofthedenovopurinenucleotidebiosynthesis AT helenemunierlehmann journeyintotheregulatorysecretsofthedenovopurinenucleotidebiosynthesis |